top of page
PHOTO-2025-08-01-12-06-21 3_edited.jpg

SYNAPTA CLINICAL RESEARCH CENTRE

ABOUT US

Synapta Clinical Research Centre, based in Durban, conducts world-class medical trials to advance treatment for conditions such as diabetes, hypertension, asthma, HIV, and more. All studies are provided at no cost to participants, with free medical assessments like ECGs, lung function tests, and blood work, plus travel cost reimbursement. Conveniently located in the Durban Medical Centre, Synapta offers a safe, accessible, and caring environment where every participant contributes to shaping better healthcare solutions for the future.

CLINICAL TRIALS FAQ

ARE TRIALS SAFE?

Yes. Clinical trials are governed by rigorous regulatory and ethical standards. They follow a structured, phased approach and require informed consent, with continuous oversight to protect participants and minimise risk.

WHAT TO EXPECT ASA CLINICAL TRIALS PARTICIPANT?

Participants undergo screening, provide informed consent, and receive comprehensive study information.
The process includes regular monitoring, with clear communication of potential risks and benefits.

HOW MUCH DOES TRIALS TREATMENT COST?

There is typically no cost to you for the treatments, as these expenses are covered by the trial sponsors.

CLINICAL TRIALS- PHASES

PHASE 1

SAFETY IS ASSESSED IN A SMALL GROUP OF PARTICIPANTS

PHASE 2

EFFICACY IS EVALUATED IN A LARGER PATIENT SAMPLE

PHASE 3

TREATMENT IS COMPARED TO STANDARD THERAPIES WITHIN A DIVERSE POPULATION

PHASE 4

SAFETY & EFFICACY IS MONITORED POST-APPROVAL

Synapta predominantly conducts Phase 3 and 4 trials, focusing on confirming a treatment's effectiveness and monitoring its long-term performance in real-world settings. By adhering to strict ethical and scientific standards, clinical trials provide patients with access to cutting-edge treatments while prioritizing their safety and well-being. Thus, participating in clinical trials contributes to medical advancements and improves patient care without subjecting individuals to undue risk.

© 2025 EMIN8 MARKETING

  • Screenshot 2025-04-07 at 12_edited_edited
  • Screenshot 2025-04-06 at 19_edited_edited_edited_edited
  • Screenshot 2025-04-06 at 19_edited_edited_edited
  • Screenshot 2025-04-06 at 19_edited_edited
  • Screenshot 2025-04-06 at 19_edited_edited
  • Screenshot 2025-04-06 at 19_edited_edited
bottom of page